<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2023-29-4-380-391</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-2287</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Некоторые особенности поражения органов-мишеней у лиц с хронической сердечной недостаточностью, инфицированных вирусом иммунодефицита человека, в зависимости от контроля артериального давления</article-title><trans-title-group xml:lang="en"><trans-title>Target organ damage in people with chronic heart failure infected with human immunodeficiency virus depending on blood pressure control</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3336-229X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горячева</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Goryacheva</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Горячева Ольга Георгиевна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней № 2 ФГБОУ ВО ПГМУ им. акад. Е.А. Вагнера Минздрава России.</p><p>ул. Братьев Игнатовых, д. 2, Пермь</p><p>Тел.: 8 (342) 221-67-84</p></bio><bio xml:lang="en"><p>Olga G. Goryacheva - Candidate of Medical Sciences, Associate Professor, Department of Propaedeutics of Internal Diseases No. 2, Perm State Medical University Named After Academician E.A. Wagner.</p><p>2 Ignatov Brothers str., Perm</p><p>Phone: 8 (342) 221-67-84</p></bio><email xlink:type="simple">o.goryacheva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное образовательное учреждение высшего образования «Пермский государственный медицинский университет имени академика Е.А. Вагнера» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Perm State Medical University Named After Academician E.A. Wagner<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2023</year></pub-date><volume>29</volume><issue>4</issue><fpage>380</fpage><lpage>391</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Горячева О.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Горячева О.Г.</copyright-holder><copyright-holder xml:lang="en">Goryacheva O.G.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/2287">https://htn.almazovcentre.ru/jour/article/view/2287</self-uri><abstract><p>Цель исследования — изучить особенности поражения органов-мишеней у больных с хронической сердечной недостаточностью (ХСН), инфицированных вирусом иммунодефицита человека (ВИЧ), в зависимости от контроля артериального давления (АД) в рамках одномоментного клинического исследования. Материалы и методы. В условиях многопрофильного стационара проведено обследование 240 больных с ВИЧ-инфекцией. Диагноз ХСН подтверждался определением в плазме крови уровня N-терминального фрагмента мозгового натрийуретического пептида (NT-proBNP), эхокардиографическими критериями и совокупностью клинических признаков. В дальнейшем были выбраны больные с ХСН и повышенным АД ≥ 140/90 мм рт. ст. (40 человек) и с АД от 91/61 до 139/89 мм рт. ст. (76 человек). Всем больным проведено изучение в сыворотке крови уровня тканевого ингибитора металлопротеиназы-1 (TIMP-1), цистатина С для оценки фильтрационной функции почек, а также неинвазивная артериография с определением дневного АД в течение 3 часов с применением медицинского оборудования TensioMed ArterioGraph 24 (Великобритания). Полученные данные обрабатывались с применением программы Statistica 13.0 (Россия). Результаты. У больных с ХСН и ВИЧ-инфекцией, имеющих артериальную гипертензию (АГ), повышение АД было ассоциировано с субклиническим поражением артерий, проявляющимся увеличением индексов аугментации и скорости пульсовой волны, а также повышением концентрации TIMP-1 в сыворотке крови. Повышение АД сопровождалось снижением фильтрационной функции почек, что подтверждалось более высоким уровнем цистатина С сыворотки крови и более низкой скоростью клубочковой фильтрации, рассчитанной на основании цистатина С по формуле CKD-EPIcys. Поражение сердечной мышцы у этих пациентов ассоциировано с более частой диастолической дисфункцией левого желудочка, гипертрофией левого желудочка (ГЛЖ) и расширением левого предсердия, с большей частотой клапанных пороков сердца, тромбоцитопенией и дефицитом сывороточного железа в анамнезе, а также приемом ингибиторов протеазы и нуклеозидных ингибиторов обратной транскриптазы. Заключение. У больных с ВИЧ-инфекцией и ХСН, имеющих АГ, АД ≥ 140/90 мм рт. ст. ассоциировано с субклиническим поражением артериальной стенки, фильтрационного аппарата почек и миокарда, в большей степени по типу диастолической дисфункции, ГЛЖ и дилатации левого предсердия. Применение ингибиторов протеазы и нуклеозидных ингибиторов обратной транскриптазы чаще встречается у лиц с АД ≥ 140/90 мм рт. ст.</p></abstract><trans-abstract xml:lang="en"><p>Objective. To study target organ damage in patients with chronic heart failure (CHF) infected with the human immunodeficiency virus (HIV), depending on the control of blood pressure (BP) in a single-stage clinical study. Design and methods. We examined 240 patients with HIV infection in a multidisciplinary hospital. The diagnosis of CHF was confirmed by the plasma level of the N-terminal fragment of the brain natriuretic peptide (NT-proBNP), echocardiographic criteria, and clinical signs. Subsequently, patients with CHF and elevated BP ≥ 140/90 mm Hg (40 people) and with BP from 91/61 to 139/89 mm Hg (76 people) were selected. In all patients we assessed serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) and cystatin C to assess renal filtration function. We also performed non-invasive arteriography with the determination of daytime BP for 3 hours using TensioMed ArterioGraph 24 (Great Britain). The data were processed using the Statistica 13.0 program. Results. In patients with CHF and HIV infection BP ≥ 140/90 mm Hg was associated with subclinical arterial disease, manifested by an increase in augmentation indices and pulse wave velocity, as well as an increase in serum level of TIMP-1. It was also accompanied by a decrease in the renal filtration function, which was confirmed by a higher serum level of cystatin C and a lower glomerular filtration rate calculated on the basis of cystatin C using the CKD-EPIcys. Myocardial remodeling in patients with CHF, HIV and elevated BP ≥ 140/90 mm Hg is presented by a more frequent left ventricular diastolic dysfunction, left ventricular hypertrophy (LVH), and left atrial dilatation. In patients with CHF and HIV infection, BP ≥ 140/90 mm Hg is associated with a higher incidence of heart failure, thrombocytopenia and a history of serum iron deficiency, as well as the intake of protease inhibitors and nucleoside reverse transcriptase inhibitors. Conclusions. In patients with HIV infection and CHF, an increase in BP ≥ 140/90 mm Hg is associated with the subclinical damage of arterial wall, kidneys and myocardium (mainly diastolic dysfunction, LVH and left atrial dilatation). The use of protease inhibitors and nucleoside reverse transcriptase inhibitors is more common in individuals with elevated BP ≥ 140/90 mm Hg.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальное давление</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>ВИЧ-инфекция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>blood pressure</kwd><kwd>chronic heart failure</kwd><kwd>HIV infection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lima MAC, Cunha GHD, Galvão MTG, Rocha RP, Franco KB, Fontenele MSM. Systemic arterial hypertension in people living with HIV/AIDS: integrative review. Rev Bras Enferm. 2017;70(6):1309–1317. doi:10.1590/0034-7167-2016-0416</mixed-citation><mixed-citation xml:lang="en">Lima MAC, Cunha GHD, Galvão MTG, Rocha RP, Franco KB, Fontenele MSM. Systemic arterial hypertension in people living with HIV/AIDS: integrative review. Rev Bras Enferm. 2017;70(6):1309–1317. doi:10.1590/0034-7167-2016-0416</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Feinstein MJ, Steverson AB, Ning H, Pawlowski AE, Schneider D, Ahmad FS et al. Adjudicated heart failure in HIV-infected and uninfected men and women. J Am Heart Assoc. 2018;7(21):e009985. doi:10.1161/JAHA.118.009985</mixed-citation><mixed-citation xml:lang="en">Feinstein MJ, Steverson AB, Ning H, Pawlowski AE, Schneider D, Ahmad FS et al. Adjudicated heart failure in HIV-infected and uninfected men and women. J Am Heart Assoc. 2018;7(21):e009985. doi:10.1161/JAHA.118.009985</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rogalska-Płońska M, Rogalski P, Leszczyszyn-Pynka M, Stempkowska J, Kocbach P, Kowalczuk-Kot A et al. Hypertension, dyslipidaemia, and cardiovascular risk in HIV-infected adults in Poland. Kardiol Pol. 2017;75(12):1324–1331. doi:10.5603/KP.a2017.0148</mixed-citation><mixed-citation xml:lang="en">Rogalska-Płońska M, Rogalski P, Leszczyszyn-Pynka M, Stempkowska J, Kocbach P, Kowalczuk-Kot A et al. Hypertension, dyslipidaemia, and cardiovascular risk in HIV-infected adults in Poland. Kardiol Pol. 2017;75(12):1324–1331. doi:10.5603/KP.a2017.0148</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Okyere J, Ayebeng C, Owusu BA, Dickson KS. Prevalence and factors associated with hypertension among older people living with HIV in South Africa. BMC Public Health. 2022;22(1):1684. doi:10.1186/s12889-022-14091-y</mixed-citation><mixed-citation xml:lang="en">Okyere J, Ayebeng C, Owusu BA, Dickson KS. Prevalence and factors associated with hypertension among older people living with HIV in South Africa. BMC Public Health. 2022;22(1):1684. doi:10.1186/s12889-022-14091-y</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y, Chen X, Wijayabahu A, Zhou Z, Yu B, Spencer EC et al. Cumulative HIV viremia copy-years and hypertension in people living with HIV. Curr HIV Res. 2020;18(3):143–153. doi:10.2174/1570162X18666200131122206</mixed-citation><mixed-citation xml:lang="en">Xu Y, Chen X, Wijayabahu A, Zhou Z, Yu B, Spencer EC et al. Cumulative HIV viremia copy-years and hypertension in people living with HIV. Curr HIV Res. 2020;18(3):143–153. doi:10.2174/1570162X18666200131122206</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Сафарова А. Ф., Ахметов Р. Е., Виллевальде С. В. Роль миокардиального фиброза в развитии ремоделирования левого желудочка и современные методы его оценки. Клиническая фармакология и терапия. 2011;20(3):71–74</mixed-citation><mixed-citation xml:lang="en">Safarova AF, Akhmetov RE, Villevalde SV. The role of myocardial fibrosis in the development of left ventricular remodeling and modern methods of its assessment. Clin Pharmacol Ther. 2011;20(3):71–74. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786</mixed-citation><mixed-citation xml:lang="en">Kobalava JD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russ J Cardiol. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913. doi:10.1016/s0140-6736(02)11911-8</mixed-citation><mixed-citation xml:lang="en">Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913. doi:10.1016/s0140-6736(02)11911-8</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Van Zoest RA, van den Born BH, Reiss P. Hypertension in people living with HIV. Curr Opin HIV AIDS. 2017;12(6):513–522. doi:10.1097/COH.0000000000000406</mixed-citation><mixed-citation xml:lang="en">Van Zoest RA, van den Born BH, Reiss P. Hypertension in people living with HIV. Curr Opin HIV AIDS. 2017;12(6):513–522. doi:10.1097/COH.0000000000000406</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cunha GHD, Lima MAC, Galvão MTG, Fechine FV, Fontenele MSM, Siqueira LR. Prevalence of arterial hypertension and risk factors among people with acquired immunodeficiency syndrome. Rev Lat Am Enfermagem. 2018;26:e3066. doi:10.1590/1518-8345.2684.3066</mixed-citation><mixed-citation xml:lang="en">Cunha GHD, Lima MAC, Galvão MTG, Fechine FV, Fontenele MSM, Siqueira LR. Prevalence of arterial hypertension and risk factors among people with acquired immunodeficiency syndrome. Rev Lat Am Enfermagem. 2018;26:e3066. doi:10.1590/1518-8345.2684.3066</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017;11(8):530–540. doi:10.1016/j.jash.2017.06.004</mixed-citation><mixed-citation xml:lang="en">Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017;11(8):530–540. doi:10.1016/j.jash.2017.06.004</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jackson IL, Okonta JM, Ukwe CV. HIV and hypertension-related knowledge and medication adherence in HIV seropositive persons with hypertension. J Public Health (Oxf). 2022;44(1):e79– e87. doi:10.1093/pubmed/fdaa221</mixed-citation><mixed-citation xml:lang="en">Jackson IL, Okonta JM, Ukwe CV. HIV and hypertension-related knowledge and medication adherence in HIV seropositive persons with hypertension. J Public Health (Oxf). 2022;44(1):e79– e87. doi:10.1093/pubmed/fdaa221</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mutengo KH, Masenga SK, Mwesigwa N, Patel KP, Kirabo A. Hypertension and human immunodeficiency virus: a paradigm for epithelial sodium channels? Front Cardiovasc Med. 2022;9:968184. doi:10.3389/fcvm.2022.968184</mixed-citation><mixed-citation xml:lang="en">Mutengo KH, Masenga SK, Mwesigwa N, Patel KP, Kirabo A. Hypertension and human immunodeficiency virus: a paradigm for epithelial sodium channels? Front Cardiovasc Med. 2022;9:968184. doi:10.3389/fcvm.2022.968184</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Abioye AI, Andersen CT, Sudfeld CR, Fawzi WW. Anemia, iron status, and HIV: a systematic review of the evidence. Adv Nutr. 2020;11(5):1334–1363. doi:10.1093/advances/nmaa037</mixed-citation><mixed-citation xml:lang="en">Abioye AI, Andersen CT, Sudfeld CR, Fawzi WW. Anemia, iron status, and HIV: a systematic review of the evidence. Adv Nutr. 2020;11(5):1334–1363. doi:10.1093/advances/nmaa037</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health. 2021;13(2):98–109. doi:10.1093/inthealth/ihaa036. PMID: 32623456</mixed-citation><mixed-citation xml:lang="en">Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health. 2021;13(2):98–109. doi:10.1093/inthealth/ihaa036. PMID: 32623456</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hansson J, Lind L, Hulthe J, Sundström J. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil. 2009;16(3):297–303. doi:10.1097/HJR.0b013e3283213108</mixed-citation><mixed-citation xml:lang="en">Hansson J, Lind L, Hulthe J, Sundström J. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil. 2009;16(3):297–303. doi:10.1097/HJR.0b013e3283213108</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Simon F, Bergeron D, Larochelle S, Lopez-Vallé CA, Genest H, Armour A et al. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns. 2012;38(3):421–427. doi:10.1016/j.burns.2011.09.001</mixed-citation><mixed-citation xml:lang="en">Simon F, Bergeron D, Larochelle S, Lopez-Vallé CA, Genest H, Armour A et al. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns. 2012;38(3):421–427. doi:10.1016/j.burns.2011.09.001</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Nie QH, Duan GR, Luo XD, Xie YM, Luo H, Zhou YX et al. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol. 2004;10(1):86–90. doi:10.3748/wjg.v10.i1.86</mixed-citation><mixed-citation xml:lang="en">Nie QH, Duan GR, Luo XD, Xie YM, Luo H, Zhou YX et al. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol. 2004;10(1):86–90. doi:10.3748/wjg.v10.i1.86</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wang BL, Tu YY, Fu JF, Zhong YX, Fu GQ, Tian XX et al. Unbalanced MMP/TIMP-1 expression during the development of experimental pulmonary fibrosis with acute paraquat poisoning. Mol Med Rep. 2011;4(2):243–248. doi:10.3892/mmr.2011.425</mixed-citation><mixed-citation xml:lang="en">Wang BL, Tu YY, Fu JF, Zhong YX, Fu GQ, Tian XX et al. Unbalanced MMP/TIMP-1 expression during the development of experimental pulmonary fibrosis with acute paraquat poisoning. Mol Med Rep. 2011;4(2):243–248. doi:10.3892/mmr.2011.425</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fragao-Marcues M, Miranda I, Martins D, Barroso I, Mendes C, Pereira-Neves A et al. Atrial matrix remodeling in atrial fibrillation patients with aortic stenosis. BMC Cardiovasc Disord. 2020;20(1):468. doi:10.1186/s12872-020-01754-0</mixed-citation><mixed-citation xml:lang="en">Fragao-Marcues M, Miranda I, Martins D, Barroso I, Mendes C, Pereira-Neves A et al. Atrial matrix remodeling in atrial fibrillation patients with aortic stenosis. BMC Cardiovasc Disord. 2020;20(1):468. doi:10.1186/s12872-020-01754-0</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">de Brouwer P, Bikker FJ, Brand HS, Kaman WE. Is TIMP-1 a biomarker for periodontal disease? A systematic review and meta-analysis. J Periodontal Res. 2022;57(2):235–245. doi:10.1111/jre.12957</mixed-citation><mixed-citation xml:lang="en">de Brouwer P, Bikker FJ, Brand HS, Kaman WE. Is TIMP-1 a biomarker for periodontal disease? A systematic review and meta-analysis. J Periodontal Res. 2022;57(2):235–245. doi:10.1111/jre.12957</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jayashree K, Yasir M, Senthilkumar GP, Ramesh Babu K, Mehalingam V, Mohanraj PS. Circulating matrix modulators (MMP-9 and TIMP-1) and their association with severity of diabetic retinopathy. Diabetes Metab Syndr. 2018;12(6):869–873. doi:10.1016/j.dsx.2018.05.006</mixed-citation><mixed-citation xml:lang="en">Jayashree K, Yasir M, Senthilkumar GP, Ramesh Babu K, Mehalingam V, Mohanraj PS. Circulating matrix modulators (MMP-9 and TIMP-1) and their association with severity of diabetic retinopathy. Diabetes Metab Syndr. 2018;12(6):869–873. doi:10.1016/j.dsx.2018.05.006</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Rajzer M, Wojciechowska W, Kameczura T, Olszanecka A, Fedak D, Terlecki M et al. The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Arch Med Sci. 2017;13(4):760–770. doi:10.5114/aoms.2016.58825</mixed-citation><mixed-citation xml:lang="en">Rajzer M, Wojciechowska W, Kameczura T, Olszanecka A, Fedak D, Terlecki M et al. The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Arch Med Sci. 2017;13(4):760–770. doi:10.5114/aoms.2016.58825</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Masenga SK, Elijovich F, Koethe JR, Hamooya BM, Heimburger DC, Munsaka SM et al. Hypertension and metabolic syndrome in persons with HIV. Curr Hypertens Rep. 2020;22(10):78. doi:10.1007/s11906-020-01089-3</mixed-citation><mixed-citation xml:lang="en">Masenga SK, Elijovich F, Koethe JR, Hamooya BM, Heimburger DC, Munsaka SM et al. Hypertension and metabolic syndrome in persons with HIV. Curr Hypertens Rep. 2020;22(10):78. doi:10.1007/s11906-020-01089-3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
